Relmada Therapeutics Announces Closing of Public Offering and Full Exercise of Over-Allotment Option

See more here


Relmada Therapeutics Announces Pricing of Upsized Public Offering of Common Stock

See more here


AllianceChicago to Offer Wellsheet’s Predictive Clinical Workflow Platform Integrated with athenahealth’s EHR 

Wellsheet Integration with athenaOne to Empower Primary Care Clinicians in Community Health Centers

See more here


Venatorx Pharmaceuticals Names Scott McConnell, Pharm.D. as Vice President, Medical Affairs

See more here


Immunome Announces Submission of an Investigational New Drug (IND) Application for IMM-BCP-01 for the Treatment of COVID-19

IMM-BCP-01 targets three non-overlapping regions on the Spike protein to provide broad coverage across CDC current and former variants of concern

– IMM-BCP-01 elicits multi-modal activity in pre-clinical testing including ACE2 and non-ACE2 dependent neutralization, as well as natural viral clearance mechanisms

See more here


Immunome Reports Third Quarter 2021 Financial Results

– IMM-BCP-01 Progressing Towards IND Filing –

See more here


Renovacor Announces Third Quarter 2021 Financial Results and Provides Corporate Update

Debuted as a public company and strengthened liquidity position with $95.1 million in gross proceeds from the business combination with Chardan Healthcare Acquisition 2 Corp and concurrent PIPE financing

Released topline preclinical data demonstrating feasibility of REN-001 to transduce a large animal heart via local infusion at low vector doses

Strengthened company leadership with key appointments including Matthew Killeen, Ph.D., as CSO, and Elizabeth White, Ph.D., as CBO and SVP of Operations

See more here


Data from ImmunoGenesis’ Lead Programs Presented in Six Posters at Society for Immunotherapy of Cancer (SITC) Conference

See more here


Relmada Therapeutics Provides Corporate Update and Reports Third Quarter 2021 Financial Results 

See more here